Cargando…
S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072008/ http://dx.doi.org/10.1186/2051-1426-2-S2-I2 |
| _version_ | 1782322888442904576 |
|---|---|
| author | Schmoll, H Wittig, BW Arnold, DA Riera-Knorrenschild, JRK Nietsche, DN Kroening, HK Mayer, FM Andel, JA Ziebermayr, RZ Scheithauer, WS |
| author_facet | Schmoll, H Wittig, BW Arnold, DA Riera-Knorrenschild, JRK Nietsche, DN Kroening, HK Mayer, FM Andel, JA Ziebermayr, RZ Scheithauer, WS |
| author_sort | Schmoll, H |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4072008 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-40720082014-06-27 S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial Schmoll, H Wittig, BW Arnold, DA Riera-Knorrenschild, JRK Nietsche, DN Kroening, HK Mayer, FM Andel, JA Ziebermayr, RZ Scheithauer, WS J Immunother Cancer Invited Speaker Presentation BioMed Central 2014-03-12 /pmc/articles/PMC4072008/ http://dx.doi.org/10.1186/2051-1426-2-S2-I2 Text en Copyright © 2014 Schmoll et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Invited Speaker Presentation Schmoll, H Wittig, BW Arnold, DA Riera-Knorrenschild, JRK Nietsche, DN Kroening, HK Mayer, FM Andel, JA Ziebermayr, RZ Scheithauer, WS S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial |
| title | S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial |
| title_full | S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial |
| title_fullStr | S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial |
| title_full_unstemmed | S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial |
| title_short | S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial |
| title_sort | s5. proffered paper: maintenance therapy of metastatic colorectal carcinoma with the tlr-9 agonist mgn1703: clinical and immunological predictive pretreatment factors of activity in the impact trial |
| topic | Invited Speaker Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072008/ http://dx.doi.org/10.1186/2051-1426-2-S2-I2 |
| work_keys_str_mv | AT schmollh s5profferedpapermaintenancetherapyofmetastaticcolorectalcarcinomawiththetlr9agonistmgn1703clinicalandimmunologicalpredictivepretreatmentfactorsofactivityintheimpacttrial AT wittigbw s5profferedpapermaintenancetherapyofmetastaticcolorectalcarcinomawiththetlr9agonistmgn1703clinicalandimmunologicalpredictivepretreatmentfactorsofactivityintheimpacttrial AT arnoldda s5profferedpapermaintenancetherapyofmetastaticcolorectalcarcinomawiththetlr9agonistmgn1703clinicalandimmunologicalpredictivepretreatmentfactorsofactivityintheimpacttrial AT rieraknorrenschildjrk s5profferedpapermaintenancetherapyofmetastaticcolorectalcarcinomawiththetlr9agonistmgn1703clinicalandimmunologicalpredictivepretreatmentfactorsofactivityintheimpacttrial AT nietschedn s5profferedpapermaintenancetherapyofmetastaticcolorectalcarcinomawiththetlr9agonistmgn1703clinicalandimmunologicalpredictivepretreatmentfactorsofactivityintheimpacttrial AT kroeninghk s5profferedpapermaintenancetherapyofmetastaticcolorectalcarcinomawiththetlr9agonistmgn1703clinicalandimmunologicalpredictivepretreatmentfactorsofactivityintheimpacttrial AT mayerfm s5profferedpapermaintenancetherapyofmetastaticcolorectalcarcinomawiththetlr9agonistmgn1703clinicalandimmunologicalpredictivepretreatmentfactorsofactivityintheimpacttrial AT andelja s5profferedpapermaintenancetherapyofmetastaticcolorectalcarcinomawiththetlr9agonistmgn1703clinicalandimmunologicalpredictivepretreatmentfactorsofactivityintheimpacttrial AT ziebermayrrz s5profferedpapermaintenancetherapyofmetastaticcolorectalcarcinomawiththetlr9agonistmgn1703clinicalandimmunologicalpredictivepretreatmentfactorsofactivityintheimpacttrial AT scheithauerws s5profferedpapermaintenancetherapyofmetastaticcolorectalcarcinomawiththetlr9agonistmgn1703clinicalandimmunologicalpredictivepretreatmentfactorsofactivityintheimpacttrial |